Search Results
348 results
Your search is now limited to «Celgene» expert search.
STAT 01/22/2019 04:30
How Celgene leaves a legacy of chutzpah in science and drug pricing.
More from STAT:
WN.com 01/21/2019 22:44
2019 began with a healthy dose of M&A deals, but I believe the most interesting deal of the year is between Bristol Myers (BMY) and Celgene (CELG.
More from WN.com:
Zacks.com 01/21/2019 10:10
For the most recent quarter, Celgene was expected to post earnings of $2.24 per share, but it reported $2.29 per share instead, representing a surprise of 2.23.
More from Zacks.com:
MedCity News 01/18/2019 14:12
Fresh on the heels of the first major biopharma acquisition deal of the year, Celgene has entered two partnerships with companies involved in immuno-oncology.
More from MedCity News:
ENDPOINTS 01/18/2019 10:04
Celgene signed 91 deals over the last 10 years, so it’s definitely among the most active deal makers.
More from ENDPOINTS:
Business Wire 01/18/2019 07:00
The collaboration includes an upfront payment and equity investment by Celgene, and potential future milestone and royalty payments.
More from Business Wire:
NASDAQ 01/17/2019 17:29
Gilead was off 48% from its all-time high in July 2015, while Celgene was down 56% from its high-water mark set in September 2017.
More from NASDAQ:
Seeking Alpha 01/17/2019 13:06
Based on today's BMS' share price, Celgene shareholders are expected to receive approximately $100, which doesn't' include a possible one-time payment of $9.00 if Celgene's ozanimod, liso-cel and bb2121 get the FDA approval.
More from Seeking Alpha:
Jan 2019 Executive Summary Oncology immunotherapy developer NantCell Inc. (a NantHealth company) raised $30mm through a crossover investment from Celgene.
More from Pharma & Medtech Business Intelligence:
Law360 01/14/2019 15:00
By Matthew Perlman Law360 (January 14, 2019, 8:00 PM EST) -- Mylan told a New Jersey federal court Friday that a consumer witness should be allowed to testify in its suit accusing Celgene of stifling generic competition for two cancer drugs because.
More from Law360:
Xconomy 01/11/2019 07:00
It made perfect sense this year, because Bristol-Myers Squibb’s (NYSE: BMY) proposed $74 billion acquisition of Celgene could be the ne plus ultra in the current wave of drug industry consolidation that everyone expects to continue this year.
More from Xconomy:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications